KRAS and non-small cell lung carcinoma: The targeted therapies for MET alterations (exon 14 splicing site mutations also known as skipping mutations or amplification), ERBB2 alterations (mutations or amplification), and KRAS G12C mutation also demonstrated promising efficacies in clinical trials, paving a way for precision medicine of NSCLC (4–8).